Enalapril therapy and thrombotic or inflammatory disturbances in essential arterial hypertension
Abstract
The authors studied enalapril therapy perspectives for correction of factors related to arterial thrombosis and inflammatory disturbances development in vascular wall among patients with essential arterial hypertension (EAR). The study included 21 males with Stage II ЕАН, and 17 healthy individuals. Echocardiography, blood rheology parameters, white blood cell functional activity, plasma levels of von Willebrand factor and ICAM, were measured. Next examination was performed after 24-week enalapril therapy (10-40 mg/d). Enalapril therapy was associated with improved blood rheology, decreased white blood cell functional activity and plasma levels of von Willebrand and ICAM, as well as left ventricular hypertrophy (LVH) regression. In EAH patients, long-term enalapril therapy resulted in LVH regression, reduced thrombo- and atherogenesis.
About the Authors
O. M. Moiseeva
НИИ кардиологии им. В.А. Алмазова МЗ РФ
Russian Federation
Russian Federation
O. A. Berkovich
НИИ кардиологии им. В.А. Алмазова МЗ РФ
Russian Federation
Russian Federation
S. V. Villevalde
НИИ кардиологии им. В.А. Алмазова МЗ РФ
Russian Federation
Russian Federation
I. V. Emelyanov
НИИ кардиологии им. В.А. Алмазова МЗ РФ
Russian Federation
Russian Federation
References
1. Шальнова С.А., Деев А.Д., Оганов Р.Г. и соавт. Роль систолического и диастолического давления для прогноза смертности от сердечно-сосудистых заболеваний//Кардиоваскулярная терапия и профилактика 2002. -№1. -С.10-15.
2. Flack J.M., Neaton J., Grimm R. et al. Blood Pressure and Mortality Among Men With Prior Myocardial Infarction // Circulation. 1995; 92: 2437-2445. JNC-VII: The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure // JAMA 2003; 289: 2560-2571.
3. Lip G.Y., Blann A.D. Does hypertension confer a prothrombotic state? Virchow's triad revisited//Circulation. 2000; 101: 218-220.
4. Lip G.Y., Blann A. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?//Cardiovasc. Res. 1997; 34: 255 -265.
5. Becker B.F., Heindl В., Kupatt C., Zahler S. Endothelial function and hemostasis//Z. Kardiol. 2000; 89: 160-167.
6. Lip G.Y.H. Target organ damage and the prothrombotic state in hypertension//Hypertension. 2000; 36: 975-977.
7. DeSouza C.A., Dengel D.R., Macko R.F et al. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension//Am. J. Hypertens. 1997; 10: 1335 -1341.
8. Safar M.E., Girerd X., Laurent S. Structural changes of large conduit arteries in hypertension//J. Hypertens. 1996; 14: 545-555.
9. Bots M.L., Hoes A.W, Koudstaal P.J. et al. Common carotid inti-ma-media thickness and the risk of stroke and myocardial infarction: The Rotterdam Study//Circulation. 1997; 96: 1432-1437.
10. Simons P.C., Algra A., Bots M.L. et al. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease)//Circulation. 1999; 100: 951-957.
11. Sander D., Kukla С., Klingelhofer J. et al. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study//Circulation. 2000; 102: 1536-1541.
12. HOPE Study Investigators. Effects of an angiotensin -converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients//N. Engl. J. Med. 2000; 342: 145-153.
13. Lonn E.M., Yusuf S., Dzavik V. et al. Effects of ramipril and vitamin E on atherosclerosis.The study to evaluate carotid ultrasound changes in patients treated with Ramipril and vitamin E (SECURE)//Circulation. 2001; 103: 919-925.
14. Тео К.К., Burton J.R., Buller C.E. et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis.The simvastatin/enalapril coronary atherosclerosis trial (SCAT)//Circulation. 2000;102: 1748-1754.
15. MacMahon S., Sharpe N., Gamble G. et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril//J. Am. Coll. Cardiol. 2000; 36: 438-443.
16. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии/Рекомендации экспертов Всероссийского общества кардиологов (ВНОК). 2001.
17. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. и др. Суточное мониторирование артериального давления (Методические вопросы). Под ред. Г.Г. Арабидзе, О.Ю. Атькова. М. 1997.
Review
For citations:
Moiseeva O.M., Berkovich O.A., Villevalde S.V., Emelyanov I.V. Enalapril therapy and thrombotic or inflammatory disturbances in essential arterial hypertension. Russian Journal of Cardiology. 2005;(4):76-80. (In Russ.)
Views:
1120
Email this article 